华恒生物
(688639)
| 流通市值：71.12亿 | | | 总市值：71.20亿 |
| 流通股本：2.49亿 | | | 总股本：2.50亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 417,922,208.58 | 422,640,063.71 | 445,305,816.8 | 393,542,579.06 |
| 应收票据及应收账款 | 359,878,297.29 | 340,225,716.25 | 270,178,635.12 | 302,479,563.29 |
| 其中：应收票据 | 52,012,639.45 | 56,408,597 | 39,225,232.98 | 31,818,446.54 |
| 应收账款 | 307,865,657.84 | 283,817,119.25 | 230,953,402.14 | 270,661,116.75 |
| 应收款项融资 | 11,890,947.21 | 34,055,142.62 | 30,597,870.27 | 26,105,569.77 |
| 预付款项 | 49,546,894.88 | 26,531,754.7 | 37,952,781.71 | 31,138,601.24 |
| 其他应收款合计 | 16,547,199.02 | 16,827,990.52 | 9,083,376.51 | 12,175,199.82 |
| 存货 | 478,747,013.3 | 406,916,559.49 | 354,258,578.97 | 263,638,391.49 |
| 其他流动资产 | 109,594,381.22 | 104,549,867.8 | 92,593,551.29 | 151,982,689.5 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,444,126,941.5 | 1,351,747,095.09 | 1,239,970,610.67 | 1,181,062,594.17 |
| 非流动资产: | | | | |
| 长期股权投资 | 7,092,123.46 | 6,853,142.53 | - | - |
| 其他非流动金融资产 | 116,589,020.3 | 116,600,033.33 | 121,543,144.73 | 120,448,953.04 |
| 固定资产 | 1,749,880,805.23 | 1,607,339,398.15 | 1,261,173,601.08 | 1,178,948,510.95 |
| 在建工程 | 1,528,622,989.18 | 1,605,626,507.86 | 1,832,371,837.41 | 1,789,385,019.48 |
| 无形资产 | 114,484,348.35 | 137,733,491.85 | 101,134,772.61 | 84,730,650.91 |
| 长期待摊费用 | 9,116,111.64 | 5,792,646.75 | - | - |
| 递延所得税资产 | 90,091,621.79 | 86,539,321.88 | 65,131,773.52 | 61,810,304.13 |
| 其他非流动资产 | 92,823,811.76 | 71,173,245.75 | 82,914,337.14 | 76,131,143.55 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,708,700,831.71 | 3,637,657,788.1 | 3,464,269,466.49 | 3,311,454,582.06 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,152,827,773.21 | 4,989,404,883.19 | 4,704,240,077.16 | 4,492,517,176.23 |
| 流动负债: | | | | |
| 短期借款 | 491,252,498.88 | 681,980,849.44 | 1,346,423,032.9 | 1,165,984,280.6 |
| 应付票据及应付账款 | 588,154,561.88 | 564,033,256.06 | 523,131,961.99 | 576,512,558.79 |
| 应付账款 | 588,154,561.88 | 564,033,256.06 | 523,131,961.99 | 576,512,558.79 |
| 合同负债 | 18,164,176.05 | 17,400,552.53 | 17,026,904.91 | 12,317,834.11 |
| 应付职工薪酬 | 33,331,134.15 | 40,038,994.05 | 24,716,815.81 | 20,773,893.49 |
| 应交税费 | 17,832,304.47 | 9,362,911.87 | 3,356,207.09 | 6,745,987.68 |
| 其他应付款合计 | 30,413,202.55 | 29,800,431.58 | 28,814,307.49 | 169,993,991.79 |
| 应付股利 | - | - | - | 141,582,343.5 |
| 一年内到期的非流动负债 | 182,257,545.74 | 225,753,281.17 | 89,503,615.3 | 52,966,073.52 |
| 其他流动负债 | 42,102,009.14 | 35,159,738.95 | 19,092,817.53 | 14,832,924.65 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,403,507,432.86 | 1,603,530,015.65 | 2,052,065,663.02 | 2,020,127,544.63 |
| 非流动负债: | | | | |
| 长期借款 | 956,573,492.64 | 637,810,021.27 | 607,587,606.99 | 458,001,709.74 |
| 递延收益 | 84,560,105.11 | 87,621,212.61 | 93,458,451.38 | 90,401,039.06 |
| 递延所得税负债 | 99,838,595.77 | 102,065,463.64 | 95,741,590.88 | 90,505,982.25 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 1,140,972,193.52 | 827,496,697.52 | 796,787,649.25 | 638,908,731.05 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 2,544,479,626.38 | 2,431,026,713.17 | 2,848,853,312.27 | 2,659,036,275.68 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 249,723,997 | 249,723,997 | 228,601,487 | 157,810,315 |
| 资本公积 | 1,210,009,473.96 | 1,209,153,973.96 | 544,280,999.47 | 612,885,746.47 |
| 减:库存股 | 53,612,725.12 | 53,612,725.12 | 53,612,725.12 | 53,612,725.12 |
| 其他综合收益 | 935,644.01 | 960,126.63 | 525,367.87 | 810,535.26 |
| 盈余公积 | 78,416,832.26 | 78,416,832.26 | 55,632,195.85 | 55,632,195.85 |
| 未分配利润 | 1,131,103,477.24 | 1,080,007,381.53 | 1,083,166,825.58 | 1,062,980,853.59 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,616,576,699.35 | 2,564,649,586.26 | 1,858,594,150.65 | 1,836,506,921.05 |
| 少数股东权益 | -8,228,552.52 | -6,271,416.24 | -3,207,385.76 | -3,026,020.5 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,608,348,146.83 | 2,558,378,170.02 | 1,855,386,764.89 | 1,833,480,900.55 |
| 负债和股东权益合计 | 5,152,827,773.21 | 4,989,404,883.19 | 4,704,240,077.16 | 4,492,517,176.23 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |